

May 9, 2019



Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week

Company to Host Fellowship and Key Opinion Leader Programs

PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to visible appearance of advanced histology, will be presented at the annual Digestive Disease Week® ("DDW"). The meeting will be held in San Diego, CA on May 18-21, 2019, and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Poster Details Below

Presentation Title: Mutational Load Predicts Risk of Progression In Barrett's Esophagus Patients With Indefinite For Dysplasia (abstract #3101561)

Session Title: Barrett's Esophagus: Diagnosis, Management and Surveillance

Session Date: May 18, 2019

Presentation Time: 12:00-2:00pm PT

The study was conducted at the Division of Gastroenterology, Zucker School of Medicine at Hofstra/Northwell, Long Island Jewish Medical Center, Northwell Health System, New Hyde Park, New York and the authors were Trindade AJ, McKinley MJ, and Alshelleh M., et. al. The study is available on the BMJ Open Gastroenterology website.

During DDW, Interpace will also be hosting a Key Opinion Leader ("KOL") program, which will focus on our PancreGEN® product for pancreatic cancer and an inaugural Fellowship program led by Dr. Tamas Gonda, a renowned Gastroenterologist at Columbia University, bringing together fellows from several New York City area academic healthcare centers to provide them background information on molecular testing for pancreatic cancer.

Jack Stover, President and CEO of Interpace, stated, "We are pleased to have the opportunity to present this most recent data on BarreGEN® at a high-profile event such as DDW, allowing us to educate the medical community on this molecular diagnostic test and further enhancing the understanding of molecular medicine in pancreatic cancer among physician leaders and fellows alike."

About DDW

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of

Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21, 2019, at the San Diego Convention Center. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at <https://ddw.org/home>.

About BarreGEN®

BarreGEN® is a molecular based assay that measures mutational load from specimens obtained from the esophagus that are suspicious for Barrett's Esophagus, one of the leading causes of Esophageal Cancer. Millions of Americans with Barrett's Esophagus undergo expensive, unnecessary procedures and therapies in efforts to identify and prevent cancer at its earliest stages. Common pathology diagnosis cannot identify which patients with non-dysplastic BE, IND or LGD will progress to cancer and which patients will not progress to esophageal carcinoma. Per the summary of a study published in 2015 in the journal Gastroenterology, "The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Carcinoma in Barrett's Esophagus."

About PancraGEN®

PancraGEN® is a molecular, pancreatic cancer risk classifier for cysts, solid lesions, and biliary strictures that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN® is 90% accurate according to clinical studies, enabling effective risk stratification of patients. Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is one of the leading causes of cancer deaths.

About Interpace Diagnostics Group

Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace's mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDx® that differentiates lung cancer of primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus, is currently being "soft launched" with key opinion leaders as we continue to gather data on this assay that will assist us in seeking favorable reimbursement as well as important clinical information. Barrett's Esophagus is a rapidly growing diagnosis that affects over three million people in the US and over time can progress to esophageal cancer. The Company's data base includes data from over 50,000 patients who have been tested using the Company's current products, including over 25,000 molecular tests for thyroid nodules. Interpace has been designated by the 2018 edition of *CIO Applications* as one of the top 10 companies for providing bioinformatics solutions. Interpace's mission is to

provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. For more information, please visit Interpace's website at www.interpacediagnostics.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the fact that success in clinical studies may not be replicated in later studies or demonstrate the clinical utility of the test, the market's acceptance of its molecular diagnostic tests and the Company's ability to retain and secure reimbursement among other things. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:

Investor Relations - Edison Group
Joseph Green
(646) 653-7030
jgreen@edisongroup.com



Source: Interpace Diagnostics Group, Inc.